STOCK TITAN

DarioHealth Corp - DRIO STOCK NEWS

Welcome to our dedicated news page for DarioHealth (Ticker: DRIO), a resource for investors and traders seeking the latest updates and insights on DarioHealth.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect DarioHealth's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of DarioHealth's position in the market.

Rhea-AI Summary
DarioHealth Corp. (DRIO) announces two new studies showcasing the effectiveness of digital stress management programs for teens. A Randomized Controlled Trial (RCT) revealed significant reductions in perceived stress, brooding, and loneliness in teens utilizing a Digital Mental Health Intervention (DMHI). Another study highlighted the positive impact of relaxation tools like breathing exercises and Cognitive Behavioral Therapy (CBT) videos on stress reduction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
none
-
Rhea-AI Summary
DarioHealth Corp. secures contracts with two national employers to provide integrated chronic condition management solutions, focusing on cardiometabolic health, musculoskeletal, and behavioral health support, including for GLP-1 medication users.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.14%
Tags
none
-
Rhea-AI Summary
DarioHealth Corp. reported a full-year 2023 revenue of $20.4 million, reflecting a decrease from 2022 due to managed B2C revenue decrease and B2B2C revenue increase. The company saw a 39% year-over-year growth in core B2B2C business. Operating expenses decreased sequentially, and the company signed multiple customers onto the Aetna platform. The acquisition of Twill, Inc. is expected to enhance profitability and revenue scale.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.66%
Tags
Rhea-AI Summary
DarioHealth Corp. (DRIO) to release financial results for Q4 2023 on March 28th, 2024, and host a conference call with CEO and President. Dial-in and webcast details provided for participants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.29%
Tags
conferences earnings
-
Rhea-AI Summary
DarioHealth Corp. presented two new clinical studies at ATTD 2024, showcasing the impact of its integrated cardiometabolic solution on weight management and diabetes, as well as improving awareness of flu vaccines in members with Type 1 and Type 2 diabetes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.6%
Tags
none
-
Rhea-AI Summary
DarioHealth Corp. (DRIO) executives to participate in Cowen 44th Annual Healthcare Conference. Erez Raphael and Rick Anderson to hold a fireside chat on March 6th, 2024. Webcast link provided for live viewing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.79%
Tags
conferences
Rhea-AI Summary
DarioHealth Corp. (DRIO) acquires Twill, Inc., expecting to nearly double pro forma revenues in 2023. The acquisition is immediately accretive to revenue and gross margins, accelerating the path to profitability. Dario also prices a $22.4 million equity financing concurrently with the acquisition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.8%
Tags
-
Rhea-AI Summary
DarioHealth Corp. (NASDAQ: DRIO) announces a new contract with a regional union to provide its cardiometabolic solution to food industry workers living with diabetes, pre-diabetes, and weight management needs, as well as those taking GLP-1 or anti-obesity medication. The company's unique approach has been successful in engaging employees in healthier behaviors, leading to long-term results. The President of Dario, Rick Anderson, is optimistic about the company's strong start in 2024, with growing demand and the launch of Aetna and several previously contracted employers in the first quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.91%
Tags
none
-
Rhea-AI Summary
DarioHealth Corp. (Nasdaq: DRIO) has secured a new contract with a national logistics company to provide cardiometabolic and GLP-1 solutions to support employees living with diabetes, pre-diabetes, hypertension, and those taking a GLP-1 medication. The integrated approach combines intelligent technologies and expert human support to deliver highly personalized experiences for optimal results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.63%
Tags
none
Rhea-AI Summary
Blue Shield of California (BSC) (Ticker: BSCA) expands its Wellvolution digital health platform to offer lifestyle medicine programs and introduces Dario, an at-home solution for high blood pressure. The expansion aims to make the platform more accessible to Spanish-speaking members and address the healthcare needs of underserved communities in California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.24%
Tags
none
DarioHealth Corp

Nasdaq:DRIO

DRIO Rankings

DRIO Stock Data

36.21M
23.92M
14.81%
29.43%
4.63%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
New York

About DRIO

DarioHealth Corp. (NASDAQ:DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition digital therapeutics platform.